Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Real data o viral hepatitis C therapy in the Czech Republic].

Vnitrni lekarstvi - 1 Jan 2000

Husová Libuše

Abstract excerpt

We reported the first real data about efficacy of interferon-free therapy of chronic hepatitis C in the Czech Republic. Patients were treated with combined therapy of paritaprevir/ritonavir + ombitasvir + dasabuvir with or without ribavirin. There were 109 patients, predominantly men - 62 (57 %), most of them infected by genotype 1b - 101 patients (93 %), minority infected by genotypes 1a (6/109, 5 %) and 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Naphthylamine
Share to Anilides
Share to Czech Republic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Ritonavir

Share to Sustained Virologic Response

Share to Uracil

Source

Identifiers

PMID: 27723987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Real data o viral hepatitis C therapy in the Czech Republic].PMID 27723987Read ↗

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.Semantic proximity Read ↗

Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study.Semantic proximity Read ↗

[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].Semantic proximity Read ↗

[Treatment of chronic hepatitis viral C: new associations].Semantic proximity Read ↗

[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].Semantic proximity Read ↗

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.Semantic proximity Read ↗

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.Semantic proximity Read ↗

[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].Semantic proximity Read ↗

[Treatment of HCV genotype 2 infection].Semantic proximity Read ↗

Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Semantic proximity Read ↗

[Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil].Semantic proximity Read ↗

[Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.